Bravecto is considered safe for most dogs when used as directed. In the largest U.S. clinical trial of 224 dogs, no serious adverse reactions were reported over a 182-day study period, and the most common side effects were mild digestive issues like vomiting (7.1%) and diarrhea (4.9%). That said, the FDA has required a specific warning on Bravecto and all products in its drug class about potential neurological side effects, so the safety picture has some nuance worth understanding.
How Bravecto Works
Bravecto’s active ingredient, fluralaner, kills fleas and ticks by targeting parts of their nervous system that don’t work the same way in mammals. Specifically, it blocks chloride channels in insect nerve cells, causing overstimulation and death. Dogs absorb fluralaner into their bloodstream, so when a flea or tick feeds, it ingests a lethal dose. This selectivity for insect biology over mammalian biology is the core reason Bravecto has a wide safety margin in dogs.
One dose protects against fleas and ticks for 12 weeks, which is longer than most monthly alternatives. The drug is stored in fat tissue and released slowly into the bloodstream over that period.
Common Side Effects
In the pivotal U.S. field study, side effects were tracked in 224 dogs receiving Bravecto and 70 dogs receiving a conventional flea and tick product. The results were reassuring: Bravecto’s side effect rates were comparable to, and in some cases lower than, the control group.
- Vomiting: 7.1% of Bravecto dogs vs. 14.3% of control dogs
- Decreased appetite: 6.7% vs. 0%
- Lethargy: 5.4% vs. 7.1%
- Diarrhea: 4.9% vs. 2.9%
- Excessive thirst: 1.8% vs. 4.3%
- Flatulence: 1.3% vs. 0%
Most of these reactions are mild and resolve on their own. In one laboratory study, a dog developed lip swelling within an hour of taking Bravecto, which cleared up by the next morning without treatment. Decreased appetite is the one side effect that showed up more often in the Bravecto group than the control, so it’s worth watching your dog’s eating habits for the first day or two after dosing.
The FDA’s Neurological Warning
In 2018, the FDA issued a fact sheet noting that isoxazoline products, the drug class that includes Bravecto, have been associated with neurological reactions in some dogs and cats. These include muscle tremors, loss of coordination (ataxia), and seizures. The FDA now requires this information on the product label.
These events are uncommon. They were not observed in the main clinical trial, but they have appeared in post-approval reports, where veterinarians and pet owners voluntarily report problems after a product reaches the broader market. Because these reports are voluntary, it’s not possible to calculate an exact rate or confirm that the drug caused every reported event. Still, the pattern was consistent enough for the FDA to flag it.
Dogs with a history of seizures or neurological conditions are at higher risk. If your dog has epilepsy or has had seizures before, this is an important conversation to have with your vet before starting any isoxazoline product.
Post-Approval Reports
Beyond the controlled clinical trial, voluntary adverse event reports paint a broader picture of what some dogs experience. Listed in order of how frequently they’re reported: vomiting, lethargy, diarrhea (sometimes with blood), loss of appetite, itching, excessive thirst, seizures, allergic reactions (hives, swelling, redness), skin issues (crusts, pustules, rash), and tremors or loss of coordination.
Reports involving breeding females have included birth defects such as limb deformities and cleft palate, as well as stillbirth and abortion. While Merck states that Bravecto chews have been evaluated in breeding, pregnant, and lactating dogs, the company also acknowledges that adverse events have been reported in breeding females. If your dog is pregnant or you’re planning to breed, discuss the risks and alternatives with your vet.
Safety in Dogs With the MDR1 Gene Mutation
Certain breeds, especially Collies, Australian Shepherds, and related herding dogs, carry a genetic mutation called MDR1 that makes them more sensitive to some drugs. Many owners of these breeds are understandably cautious about any systemic medication. The good news here is clear: in a dedicated safety study, Collies homozygous for the MDR1 mutation received fluralaner at three times the maximum clinical dose. No adverse events were observed, and no signs of neurotoxicity appeared even during the period of peak drug concentrations in the blood. Bravecto appears well tolerated in dogs with this genetic sensitivity.
What Happens With Repeated Dosing
Because Bravecto stays in the body for months, one reasonable concern is whether the drug builds up over time. In a margin-of-safety study, dogs received fluralaner at one, three, and five times the label dose every four months for six consecutive doses. Blood levels of the drug did accumulate, reaching a steady state by around the fourth dose (roughly one year of use). At the standard dose, this accumulation did not produce serious problems.
At three times the label dose, one dog in the study developed seizures and blood vessel inflammation that were considered possibly drug-related. At the normal dose, these effects were not seen. This is a typical finding in margin-of-safety studies, which deliberately push doses well beyond what any pet would receive, precisely to identify where problems begin. It does reinforce, though, that correct dosing based on your dog’s weight matters.
Drug Interactions
No specific drug-to-drug interactions between Bravecto and common canine medications like anti-inflammatories or heartworm preventatives have been identified in the product’s labeling or FDA communications. Bravecto is frequently used alongside heartworm prevention without reported issues. That said, if your dog takes anti-seizure medication or other drugs that affect the nervous system, mention it to your vet before adding Bravecto.
Putting the Risk in Perspective
No flea and tick product is completely without risk, and the control group in Bravecto’s clinical trial had its own set of side effects at similar or higher rates. Bravecto has been on the market since 2014 and has been administered to millions of dogs worldwide. For the vast majority, it works as intended with no problems. The dogs most likely to have issues are those with a seizure history or neurological conditions, and those receiving incorrect doses for their weight. If your dog is otherwise healthy and properly dosed, Bravecto carries a low risk profile consistent with other widely used flea and tick products.